Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 target
Global brokerage Jefferies has initiated coverage on Anthem Biosciences with a Buy rating and a price target of Rs 1,050, citing the company’s differentiated capabilities across small- and large-molecule therapeutics, strong return ratios and a healthy growth runway. The target price implies an upside of around 20% from Anthem Biosciences’ current market price of Rs…